Dermatology practices face an average claim denial rate of around 14%, nearly three times the 5% benchmark considered acceptable across other specialties. Approximately two-thirds of denied dermatology claims are recoverable with proper appeals. The problem is not coverage. The problem is process, documentation, and coding accuracy. This guide breaks down the most common causes of dermatology claim denials and provides straight-to-the-point prevention strategies you can implement immediately.
Why Dermatology Has Such a High Denial Rate
Three structural reasons make dermatology uniquely vulnerable to denials.
- First, many dermatologic procedures live close to the line between cosmetic and medically necessary. Excisions, laser treatments, injections, and biologics can be either depending on the clinical circumstances. Payers know this and scrutinize these claims aggressively.
- Second, dermatology coding is genuinely complex. Excision codes depend on lesion size plus margins, anatomical location, and whether the lesion was benign or malignant. Biopsy codes changed significantly in recent years. Mohs surgery has its own documentation expectations. Getting every element right requires specialty-specific knowledge.
- Third, prior authorization volume for dermatology is among the highest in medicine. Biologics for psoriasis, atopic dermatitis, and hidradenitis suppurativa drive enormous PA volume, with denial rates reaching as high as 51% for some therapies.
Causes of Dermatology Claim Denials and Prevention Strategies
Cause 1: Medical Necessity Disputes on Cosmetic-Adjacent Procedures
Payers actively look for opportunities to classify borderline procedures as cosmetic. The procedures most frequently targeted include excisions of skin lesions, Botox injections for hyperhidrosis, laser treatments for rosacea, and treatments for acne scarring. The problem often starts in the chart note. When a provider documents “patient is bothered by the appearance” or “patient requests removal for cosmetic reasons,” the payer uses that language to justify a cosmetic denial.
How to Prevent It
- Train providers and scribes to avoid aesthetic language entirely in clinical documentation
- Replace phrases like “patient bothered by appearance” with specific clinical findings
- Document bleeding, irritation, functional limitation, failed topical treatments, and occupational impacts
- Use ICD-10 codes that reflect a medical condition, not a cosmetic concern
- Never use the word “cosmetic” in a note for a medically necessary service
Cause 2: Modifier Errors
Modifier misuse accounts for approximately 22% of dermatology claim denials. Modifier 25 is required when a significant, separately identifiable E/M service is performed on the same day as a procedure. Missing Modifier 25 costs practices between $15,000 and $40,000 per year. Modifier 59 and X-modifiers (XS, XE, XP, XU) apply when two procedures that would normally be bundled were genuinely distinct services. Medicare prefers X-modifiers over plain Modifier 59 because they reduce ambiguity.
How to Prevent It
- Build Modifier 25 as a required field in encounter forms whenever an E/M is billed with a procedure
- Create documentation templates with a clear separate section for E/M work that stands independently from the procedural note
- Maintain a reference guide for your billing team mapping common code pairings to the correct modifier
- Review NCCI edit updates quarterly
- Use X-modifiers (XS for separate structure, XE for separate encounter) instead of plain Modifier 59 whenever possible
Cause 3: Excision Coding Errors
Excision codes are among the most commonly miscoded procedure types in dermatology. The fundamental rule is that the size used to select the code is the excised diameter, which equals the lesion diameter plus twice the narrowest margin, measured before local anaesthesia. Under coding margins leaves between $12,000 and $20,000 on the table annually. The code also depends on whether the lesion was benign or malignant and on anatomical location. Getting any variable wrong produces the wrong code.
How to Prevent It
- Record the lesion measurement, planned margin, and excised diameter in the procedure note before anaesthesia is administered
- Build a one-page excision coding guide mapping code ranges by size bracket, location, and benign versus malignant status
- Post the guide at every billing station
- Review the guide with new billers during onboarding
- When pathology changes a diagnosis from benign to malignant, revise the code selection and submit a corrected claim
- Use Modifier 59 when billing repair alongside excision to demonstrate the services are distinct
Cause 4: Prior Authorization Failures for Biologics and High-Cost Therapies
Missing prior authorization for biologics accounts for approximately 18% of dermatology claim denials. Biologic therapies for psoriasis, atopic dermatitis, and hidradenitis suppurativa require prior authorization from every major payer. Denials typically fall into three categories: step therapy requirements not completed or documented, severity not documented to the payer’s clinical threshold, and lab work or monitoring documentation missing.
How to Prevent It
- Check coverage and PA requirements before the prescription is written, not after a denial arrives
- Document step therapy failures with specific drug names, doses, duration, and outcome language showing inadequate response or intolerance
- Include severity scores using payer-specific tools (BSA, PASI, EASI, IGA) in every PA packet
- Attach all relevant lab work and monitoring results
- Maintain a PA tracker showing status of every open authorization and expiration dates
- Build a payer-specific PA requirement matrix and verify it at least annually
Cause 5: Biopsy Coding Errors
Why This Happens
The current biopsy code structure uses tangential, punch, and incisional technique to determine the correct code, not the size or location. Code 11102 covers tangential biopsy of a single lesion (shave, scoop, saucerise, curette). Code 11104 covers punch biopsy. Code 11106 covers incisional biopsy (wedge, deep scalpel). When providers document “biopsy performed” without specifying the technique, billing teams have to guess, and guessing produces the wrong code.
How to Prevent It
- Train providers that biopsy documentation must specify the technique: tangential, punch, or incisional
- Document the number of lesions biopsied by each technique
- Build a procedure documentation template with technique as a required field
- When multiple techniques are used in the same session, document and code each separately using base code for first lesion and add-on code for each additional lesion of the same technique
Cause 6: Place of Service and Telehealth Coding Errors
Tele dermatology is now permanent for follow-up care, but place of service coding for telehealth is one of the most inconsistent areas across payers. Medicare accepts POS 11 with Modifier 95, but many commercial payers require POS 10 (patient’s home) or POS 02 (other location). Mislabelling POS is currently a top-three reason for dermatology billing rejections. There is no universal standard. What works for Medicare does not work for every commercial plan.
How to Prevent It
- Build a payer-specific telehealth matrix documenting required POS code and modifier for each contracted payer
- Review the matrix at least annually and update it when payers send policy changes
- Add a verification step for telehealth billing requirements when a new payer comes on contract
- Flag patients being seen via telehealth within a global period (post-excision wound checks are bundled and cannot be separately billed)
Cause 7: Mohs Surgery Documentation Deficiencies
Mohs surgery is among the most audited procedures in dermatology. Documentation failures typically involve missing justification for why Mohs was selected over standard excision, incomplete stage-by-stage operative documentation, pathology reports that do not clearly support the number of stages billed, and repair codes that do not match the operative note.
How to Prevent It
- Document tumour type and location in every Mohs operative report
- Include clinical and histologic factors supporting Mohs over standard excision
- Describe each stage performed with clear documentation of what happened at each stage
- Document pathology findings at each stage including margin status
- Document the repair performed following the procedure
- Verify prior authorization requirements with each payer before scheduling Mohs procedures
Cause 8: Missing or Incorrect ICD-10 Codes
Payers reject claims with invalid codes, expired codes, codes that do not match the procedure, and diagnosis codes too vague to support medical necessity. New ICD-10-CM codes for FY 2026 include expanded options for actinic keratosis, autoimmune skin disorders, and drug-induced eruptions. Using outdated codes after October 1 results in automatic claim rejections.
How to Prevent It
- Update superbill and EHR encounter forms at every ICD-10 annual update cycle (each October 1)
- Subscribe to AAPC or AMA code update alerts
- Assign one billing team member responsibility for tracking annual ICD-10-CM changes affecting dermatology
- Build a verified, current reference list of most commonly used diagnosis codes organized by condition
- Use vague codes only when a more specific code is genuinely not supported by clinical findings
Cause 9: Timely Filing Failures
Once the filing window closes, the claim is gone regardless of coding accuracy. Medicare’s timely filing window is 12 months from date of service. Most commercial payers have shorter windows, commonly 90 to 180 days. Some plans are as short as 60 days. In a high-volume dermatology practice, claims can easily fall through the cracks past their filing window.
How to Prevent It
- Generate an alert in your practice management system for any claim not submitted within 30 days of date of service
- Set a documentation completion deadline of no more than 72 hours post-procedure for complex services like Mohs surgery
- Run a monthly aging report filtered for unsubmitted claims
- Give immediate attention to any claim sitting unsubmitted past 30 days
Cause 10: Global Period Violations
Every surgical procedure in dermatology carries a global period. Many carry 90-day global. Some carry 10-day global. During the global period, all related follow-up care is bundled into the surgical payment. Billing a separate E/M for a routine wound check within a 90-day global period will deny. As telehealth post-procedure visits increased, so did global period bundle denials.
How to Prevent It
- Flag patients who are within an active global period in your scheduling system
- Train schedulers to know whether a post-procedure follow-up visit will be billable or bundled
- Use Modifier 24 to bill separately for a new, unrelated problem addressed during a global period visit
- Document the unrelated service explicitly and keep it separate from global period follow-up documentation
How to Build a Denial Management Infrastructure?
Individual fixes for each denial type help, but the practices that truly solve their denial problem build a systematic denial management infrastructure around three core elements.
- Clean claim protocols. Every claim should pass through a pre-submission checklist verifying that diagnosis codes are current and match the service, procedure codes are correct, all required modifiers are present, prior authorization is confirmed, and place of service is correct.
- Denial tracking by root cause. Categorize every denial by specific reason. Track it in a log. If you receive five denials per month for missing Modifier 25, that is a training problem that needs systematic correction. Run monthly denial trend analysis.
- Defined appeals workflow with specialty-specific language. Create template appeal letters for each denial category using the specific clinical language and documentation framework that works for that denial type. Generic appeal letters lose. Specific, clinically grounded appeals win.
Frequently Asked Questions
What is the most common reason dermatology claims get denied?
The leading causes are cosmetic versus medical necessity disputes (40% of denials), modifier misuse (22%), missing prior authorization for biologics (18%), excision size documentation errors (12%), and duplicate claims (8%).
How does Modifier 25 work in dermatology?
Modifier 25 signals that on the same date of service, the provider performed a significant, separately identifiable E/M service beyond the pre-procedure assessment required to decide to perform the procedure. It is appropriate when a patient comes in for a procedure and the provider also evaluates a separate, distinct clinical concern. It is not appropriate when the entire E/M content of the visit was about the condition being treated by the procedure.
Why are biologic prior authorization denials so common?
Biologics are high-cost therapies, and payers apply strict clinical criteria before approving them. Denials typically involve three deficiencies: step therapy not completed, severity not documented to the payer’s threshold, or lab work missing. A strong PA submission documents every conventional therapy tried with specific drug names, doses, duration, and outcomes.
What happens if excision sizes are not measured before anaesthesia?
If the measurement is taken after anaesthesia, the tissue may have contracted or distorted, and the measurement will not accurately reflect the actual excised diameter. If the procedure note does not explicitly state that measurement occurred before anaesthesia, the payer has no way to verify that the code selected is accurate.
How should a dermatology practice handle denials citing cosmetic exclusions?
Appeal with clinical specificity. Include four elements. First, an ICD-10 code reflecting a medical condition. Second, documentation of functional impairment. Third, a chronological list of conservative treatments that were tried and failed. Fourth, a citation from an AAD clinical guideline supporting the procedure as standard of care. Strip all aesthetic language from your appeal. Reference clinical findings exclusively.
